检索
AI 对话
AI 辅写
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

Jameel Muzaffar,Tae Min Kim, Julie Brahmer,Dirk G Brockstedt,Chia-Chi Lin,Michael Chisamore, Ki Hyeong Lee,Paul D Kassner,Nuttapong Ngamphaiboon,William Ho,Nicole Nasrah, Pratibha Desai,Yin-Hsun Feng,Shang-Yin Wu, Rakesh Kumar Goyal

Journal for ImmunoTherapy of Cancer（2023）

引用 0|浏览7
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要